Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)
Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. In this randomised, double-blind, place...
Saved in:
| Published in | Lancet neurology Vol. 10; no. 7; pp. 618 - 625 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.07.2011
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality.
In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with
ClinicalTrials.gov, number
NCT00558311.
In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI −4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (−18%, −45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups.
Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH.
Actelion Pharmaceuticals. |
|---|---|
| AbstractList | Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. Methods: In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with [inline image]ClinicalTrials.gov, number [inline image]NCT00558311. Findings: In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI -4 to 33; p=0 super(.10). Poor functional outcome (GOSE score =4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (-18%, -45 to 4; p=0) super(.)10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups. Interpretation: Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH. Funding: Actelion Pharmaceuticals. Summary Background Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. Methods In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov , number NCT00558311. Findings In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI −4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (−18%, −45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups. Interpretation Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH. Funding Actelion Pharmaceuticals. Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality.BACKGROUNDClazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality.In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov, number NCT00558311.METHODSIn this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov, number NCT00558311.In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI -4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (-18%, -45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups.FINDINGSIn the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI -4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (-18%, -45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups.Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH.INTERPRETATIONClazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH.Actelion Pharmaceuticals.FUNDINGActelion Pharmaceuticals. Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov, number NCT00558311. In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI −4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (−18%, −45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups. Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH. Actelion Pharmaceuticals. Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov, number NCT00558311. In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI -4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (-18%, -45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups. Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH. Actelion Pharmaceuticals. Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with aSAH secured by surgical clipping to clazosentan (5 mg/h, n=768) or placebo (n=389) for up to 14 days (27 countries, 102 sites, inpatient and outpatient settings) using an interactive web response system. The primary composite endpoint (week 6) included all-cause mortality, vasospasm-related new cerebral infarcts, delayed ischaemic neurological deficit due to vasospasm, and rescue therapy for vasospasm. The main secondary endpoint was dichotomised extended Glasgow outcome scale (GOSE; week 12). This trial is registered with ClinicalTrials.gov, number NCT00558311. In the all-treated dataset, the primary endpoint was met in 161 (21%) of 764 clazosentan-treated patients and 97 (25%) of 383 placebo-treated patients (relative risk reduction 17%, 95% CI -4 to 33; p=0·10). Poor functional outcome (GOSE score ≤4) occurred in 224 (29%) clazosentan-treated patients and 95 (25%) placebo-treated patients (-18%, -45 to 4; p=0·10). Lung complications, anaemia, and hypotension were more common with clazosentan. Mortality (week 12) was 6% in both groups. Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome. Further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosentan in patients with aSAH. Actelion Pharmaceuticals. |
| Author | Macdonald, R Loch Bach, Doris Roux, Sébastien Vajkoczy, Peter Kassell, Neal Higashida, Randall T Mayer, Stephan A Molyneux, Andy Keller, Emanuela Wanke, Isabel Marr, Angelina Raabe, Andreas Frey, Aline |
| Author_xml | – sequence: 1 givenname: R Loch surname: Macdonald fullname: Macdonald, R Loch email: macdonaldlo@smh.ca organization: St Michael's Hospital, University of Toronto, Toronto, ON, Canada – sequence: 2 givenname: Randall T surname: Higashida fullname: Higashida, Randall T organization: University of California, San Francisco, CA, USA – sequence: 3 givenname: Emanuela surname: Keller fullname: Keller, Emanuela organization: University of Zürich, Zürich, Switzerland – sequence: 4 givenname: Stephan A surname: Mayer fullname: Mayer, Stephan A organization: Columbia University, Columbia, Washington DC, USA – sequence: 5 givenname: Andy surname: Molyneux fullname: Molyneux, Andy organization: University of Oxford, Oxford, UK – sequence: 6 givenname: Andreas surname: Raabe fullname: Raabe, Andreas organization: University of Bern, Bern, Switzerland – sequence: 7 givenname: Peter surname: Vajkoczy fullname: Vajkoczy, Peter organization: Charite Universitaetsmedizin Berlin, Berlin, Germany – sequence: 8 givenname: Isabel surname: Wanke fullname: Wanke, Isabel organization: University Hospital of Essen, Essen, Germany – sequence: 9 givenname: Doris surname: Bach fullname: Bach, Doris organization: Actelion Pharmaceuticals, Allschwil, Switzerland – sequence: 10 givenname: Aline surname: Frey fullname: Frey, Aline organization: Actelion Pharmaceuticals, Allschwil, Switzerland – sequence: 11 givenname: Angelina surname: Marr fullname: Marr, Angelina organization: Actelion Pharmaceuticals, Allschwil, Switzerland – sequence: 12 givenname: Sébastien surname: Roux fullname: Roux, Sébastien organization: Actelion Pharmaceuticals, Allschwil, Switzerland – sequence: 13 givenname: Neal surname: Kassell fullname: Kassell, Neal organization: University of Virginia, Charlottesville, VA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21640651$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkkuP0zAUhSM0iHnATwBZbJiRGrCdZwcBQhWPkUZ0UWZtOc5t48G1g-2Ayn_kP3EzLV1UQsMqyc13Tm6Oz2lyZJ2FJHnK6EtGWflqwfIqT_Oc83PGLirKaJ1OHyQnu3FZHO3vOT9OTkO4pZSzvGaPkmPOypyWBTtJfs-M_OUC2CjthEhLwLYudmC0JR4U9NF5HEe5claHOCE472XUKAjkp44dvoTBb8JaGhKGRnqpOut0SzoJa-d9J1dABtuCXzltV8j4lVYIK6P7HieXRBIv8atrHaCdkNYNjYG0wQ3wqTdSQeNS5Wz0zhhoSd_JACQj0Wu0OZ_NvyxmV_ObRcovHicPl9IEeLK7niU3Hz98nX1Or-efrmbvr1NVZDymTTVtSlYXALysJdSQ82lDqwx4w4HXjGcZK6uyLHkmKa3kdJmzTC0phXKZF3mbnSUvtr69d98HCFHg8gqMwTDcEERdZxRBVtxPVhnjnLMKyecH5K0bvMXfGKGMsarmCD3bQUOzhlb0Xq-l34i_B4pAsQWUdyF4WO4RRsVYHHFXHDG2QjAm7oojpqh7faBTOuI5j7FLbe5Vv9uqAUP_ocGLoLAiClqNJYqidfpeh7cHDtgPOxblG2wg7KNgInBBtyajB8YyOowGb_5t8B8L_AHyDQXC |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_3171_2018_4_JNS172313 crossref_primary_10_1007_s12975_013_0316_8 crossref_primary_10_1016_j_anrea_2016_09_003 crossref_primary_10_3892_ijmm_2016_2506 crossref_primary_10_3389_fsurg_2024_1467154 crossref_primary_10_3390_biom15020164 crossref_primary_10_4236_jbbs_2020_1010024 crossref_primary_10_1155_2013_651958 crossref_primary_10_1016_j_hest_2023_10_006 crossref_primary_10_1038_s41467_024_52654_2 crossref_primary_10_1161_JAHA_121_021845 crossref_primary_10_1136_rapm_2022_103999 crossref_primary_10_1007_s12975_013_0284_z crossref_primary_10_1007_s10143_023_02104_2 crossref_primary_10_1097_WNP_0000000000000275 crossref_primary_10_1016_j_bbi_2017_04_020 crossref_primary_10_1136_neurintsurg_2015_011854 crossref_primary_10_3390_ijms24108856 crossref_primary_10_1007_s00381_017_3573_0 crossref_primary_10_1186_s12974_024_03099_3 crossref_primary_10_1161_STROKEAHA_120_032001 crossref_primary_10_1097_CCM_0000000000001146 crossref_primary_10_1016_j_nrleng_2012_07_020 crossref_primary_10_1186_s12883_017_0994_z crossref_primary_10_3171_2020_7_JNS202551 crossref_primary_10_1016_j_wneu_2014_06_048 crossref_primary_10_1038_jcbfm_2014_198 crossref_primary_10_1016_j_bbi_2016_02_007 crossref_primary_10_4236_jbbs_2019_1010024 crossref_primary_10_1007_s12035_022_02788_5 crossref_primary_10_1093_neuros_nyaa192 crossref_primary_10_4103_NRR_NRR_D_24_00124 crossref_primary_10_1007_s11940_018_0501_x crossref_primary_10_1136_jnnp_2023_332889 crossref_primary_10_3390_ijms23094910 crossref_primary_10_1017_cjn_2015_288 crossref_primary_10_1007_s12028_024_01981_9 crossref_primary_10_1016_j_jstrokecerebrovasdis_2018_06_027 crossref_primary_10_1097_ANA_0b013e3182868b15 crossref_primary_10_1177_0271678X20921974 crossref_primary_10_1007_s12975_023_01191_z crossref_primary_10_3390_ijms24097832 crossref_primary_10_1177_0271678X211012110 crossref_primary_10_3390_antiox8100496 crossref_primary_10_1002_jcp_30351 crossref_primary_10_1016_S1441_2772_23_00780_9 crossref_primary_10_1155_2013_462491 crossref_primary_10_1093_bja_aew095 crossref_primary_10_1212_WNL_0000000000007862 crossref_primary_10_1007_s12028_024_02111_1 crossref_primary_10_1097_MD_0000000000034789 crossref_primary_10_1111_cns_13222 crossref_primary_10_1310_hpj4910_923 crossref_primary_10_1038_s44161_023_00347_2 crossref_primary_10_1227_neu_0000000000002277 crossref_primary_10_1097_MCC_0000000000000183 crossref_primary_10_1007_s12975_024_01234_z crossref_primary_10_1080_14656566_2021_1912013 crossref_primary_10_1161_STROKEAHA_120_033472 crossref_primary_10_1186_s40560_018_0297_5 crossref_primary_10_1001_jamaneurol_2023_1792 crossref_primary_10_1161_STROKEAHA_119_025682 crossref_primary_10_3389_fnagi_2022_899678 crossref_primary_10_3389_fneur_2021_688362 crossref_primary_10_1177_0271678X231171991 crossref_primary_10_1177_0271678X16665623 crossref_primary_10_1161_STROKEAHA_114_006365 crossref_primary_10_1016_j_neulet_2016_05_058 crossref_primary_10_3389_fphar_2022_796616 crossref_primary_10_1038_s41598_024_77321_w crossref_primary_10_1007_s12035_018_1213_7 crossref_primary_10_1007_s00115_012_3528_3 crossref_primary_10_1016_j_jcrc_2016_09_011 crossref_primary_10_3389_fneur_2014_00134 crossref_primary_10_1002_glia_23864 crossref_primary_10_1016_S1474_4422_14_70084_5 crossref_primary_10_1016_j_wneu_2023_11_049 crossref_primary_10_1016_j_brainres_2016_02_038 crossref_primary_10_1161_STROKEAHA_112_650390 crossref_primary_10_1016_S0140_6736_22_00938_2 crossref_primary_10_1155_2013_263974 crossref_primary_10_3390_jcm9030824 crossref_primary_10_1097_MCC_0b013e32835075ae crossref_primary_10_1007_s11883_017_0690_x crossref_primary_10_1007_s12028_019_00710_x crossref_primary_10_1016_j_wneu_2012_01_048 crossref_primary_10_1097_ANA_0000000000000527 crossref_primary_10_1016_j_wneu_2022_08_057 crossref_primary_10_1161_STROKEAHA_111_646836 crossref_primary_10_1002_jnr_23542 crossref_primary_10_1002_jnr_24515 crossref_primary_10_1002_14651858_CD013096_pub2 crossref_primary_10_1038_nrneurol_2011_168 crossref_primary_10_1186_s12883_022_03002_8 crossref_primary_10_3390_jcm11164642 crossref_primary_10_1111_j_1471_4159_2012_07939_x crossref_primary_10_1161_STROKEAHA_122_038881 crossref_primary_10_1155_2014_727428 crossref_primary_10_1007_s12975_024_01308_y crossref_primary_10_1007_s12975_015_0398_6 crossref_primary_10_1038_jcbfm_2013_173 crossref_primary_10_1186_1471_2377_12_32 crossref_primary_10_1080_14728222_2021_1869213 crossref_primary_10_1016_j_wneu_2019_08_155 crossref_primary_10_1016_j_jns_2014_08_012 crossref_primary_10_1093_neuros_nyx364 crossref_primary_10_1155_2014_384342 crossref_primary_10_1155_2013_560305 crossref_primary_10_1016_j_wneu_2018_07_138 crossref_primary_10_1016_j_pneurobio_2013_09_002 crossref_primary_10_1212_01_CON_0000415429_99394_e8 crossref_primary_10_1016_j_neuchi_2019_06_005 crossref_primary_10_1007_s12028_023_01713_5 crossref_primary_10_1016_j_clineuro_2025_108769 crossref_primary_10_1007_s12975_013_0300_3 crossref_primary_10_1007_s12028_020_01129_5 crossref_primary_10_1155_2013_506584 crossref_primary_10_1016_j_neurad_2014_12_002 crossref_primary_10_1155_2017_5819514 crossref_primary_10_1016_j_jns_2017_03_024 crossref_primary_10_1016_S1474_4422_11_70122_3 crossref_primary_10_1055_s_0031_1295431 crossref_primary_10_1007_s12028_015_0137_6 crossref_primary_10_1155_2014_858496 crossref_primary_10_3390_brainsci12091239 crossref_primary_10_3389_fnins_2018_00724 crossref_primary_10_1212_WNL_0000000000209690 crossref_primary_10_1016_j_artres_2018_07_004 crossref_primary_10_1007_s00228_014_1647_4 crossref_primary_10_1007_s12975_022_00995_9 crossref_primary_10_4236_ojmn_2013_34016 crossref_primary_10_1007_s10072_019_03810_w crossref_primary_10_1186_1471_2202_14_34 crossref_primary_10_3389_fneur_2024_1413632 crossref_primary_10_3389_fneur_2022_838456 crossref_primary_10_1016_j_jocn_2013_03_011 crossref_primary_10_1136_neurintsurg_2017_013410 crossref_primary_10_1093_neuros_nyaa473 crossref_primary_10_1186_cc11686 crossref_primary_10_1186_s13054_023_04452_3 crossref_primary_10_1007_s00234_021_02689_9 crossref_primary_10_1007_s12975_021_00960_y crossref_primary_10_1055_a_1238_7891 crossref_primary_10_18632_aging_203221 crossref_primary_10_3171_2022_2_JNS212914 crossref_primary_10_1007_s10143_020_01322_2 crossref_primary_10_1161_STROKEAHA_111_000008 crossref_primary_10_1007_s12028_023_01790_6 crossref_primary_10_1152_jn_00622_2024 crossref_primary_10_1038_cddis_2016_63 crossref_primary_10_3389_fnagi_2021_772036 crossref_primary_10_1007_s00101_019_0581_3 crossref_primary_10_1016_j_jocn_2016_09_028 crossref_primary_10_1007_s12028_023_01879_y crossref_primary_10_1016_j_hest_2023_12_001 crossref_primary_10_1007_s12975_013_0310_1 crossref_primary_10_1177_0271678X19863021 crossref_primary_10_1155_2013_571328 crossref_primary_10_1016_j_hest_2023_12_004 crossref_primary_10_1136_jnnp_2014_307711 crossref_primary_10_1007_s12028_019_00737_0 crossref_primary_10_1016_j_anrea_2016_08_003 crossref_primary_10_3390_brainsci12111507 crossref_primary_10_1212_WNL_0000000000002696 crossref_primary_10_1097_WNF_0000000000000085 crossref_primary_10_1186_s12883_020_02003_9 crossref_primary_10_1042_BSR20160480 crossref_primary_10_1007_s13311_020_00838_1 crossref_primary_10_1161_STROKEAHA_112_679142 crossref_primary_10_1186_s13063_017_2004_6 crossref_primary_10_1007_s12028_023_01847_6 crossref_primary_10_1016_j_wneu_2024_09_117 crossref_primary_10_1136_neurintsurg_2014_011403 crossref_primary_10_1016_j_jns_2013_07_004 crossref_primary_10_3171_2013_3_JNS121436 crossref_primary_10_1007_s12325_018_0832_8 crossref_primary_10_1021_acs_oprd_3c00131 crossref_primary_10_1016_S1474_4422_11_70189_2 crossref_primary_10_1007_s10143_024_03173_7 crossref_primary_10_1155_2014_628597 crossref_primary_10_1371_journal_pone_0116456 crossref_primary_10_1038_s41598_017_07701_y crossref_primary_10_1097_MD_0000000000001683 crossref_primary_10_1161_STROKEAHA_121_037670 crossref_primary_10_1007_s12028_023_01812_3 crossref_primary_10_1007_s00330_016_4702_y crossref_primary_10_1590_0004_282x_anp_2022_s101 crossref_primary_10_1002_ebm2_13 crossref_primary_10_1016_j_neuroscience_2012_08_002 crossref_primary_10_1016_j_jocn_2014_05_025 crossref_primary_10_1161_STROKEAHA_117_020028 crossref_primary_10_1093_brain_awab457 crossref_primary_10_1016_j_wneu_2015_02_004 crossref_primary_10_26693_jmbs04_02_159 crossref_primary_10_1177_0271678X241237070 crossref_primary_10_1016_j_jneumeth_2012_05_010 crossref_primary_10_1007_s12028_014_0039_z crossref_primary_10_1161_STROKEAHA_111_642629 crossref_primary_10_1161_STROKEAHA_124_048089 crossref_primary_10_3171_2019_4_JNS19478 crossref_primary_10_1161_STROKEAHA_111_000686 crossref_primary_10_1016_j_wneu_2019_02_188 crossref_primary_10_3171_2016_5_JNS152900 crossref_primary_10_1016_j_wnsx_2023_100160 crossref_primary_10_1038_s41598_017_16124_8 crossref_primary_10_1186_s12974_016_0709_1 crossref_primary_10_3892_mmr_2018_9640 crossref_primary_10_1055_s_0044_1801369 crossref_primary_10_1161_STR_0b013e3182587839 crossref_primary_10_1155_2015_608607 crossref_primary_10_1007_s12028_023_01747_9 crossref_primary_10_1016_j_hest_2023_11_007 crossref_primary_10_3174_ajnr_A7021 crossref_primary_10_3171_2021_7_JNS21846 crossref_primary_10_3892_mmr_2017_8074 crossref_primary_10_1016_j_jocn_2012_07_006 crossref_primary_10_1007_s12975_012_0166_9 crossref_primary_10_1007_s12975_024_01292_3 crossref_primary_10_1007_s12028_016_0318_y crossref_primary_10_3171_2016_9_JNS161119 crossref_primary_10_1007_s12975_014_0323_4 crossref_primary_10_1016_j_wneu_2021_11_096 crossref_primary_10_1016_j_hest_2025_02_003 crossref_primary_10_1016_j_jstrokecerebrovasdis_2020_105027 crossref_primary_10_2335_scs_52_258 crossref_primary_10_1007_s12975_018_0685_0 crossref_primary_10_1161_STROKEAHA_121_035699 crossref_primary_10_1016_j_wneu_2019_12_056 crossref_primary_10_3171_2019_12_JNS192744 crossref_primary_10_25259_SNI_554_2024 crossref_primary_10_1016_j_brainres_2014_10_014 crossref_primary_10_1007_s12028_021_01299_w crossref_primary_10_1007_s12028_022_01556_6 crossref_primary_10_1016_j_wneu_2024_08_097 crossref_primary_10_1080_02688697_2022_2039378 crossref_primary_10_1016_j_bbr_2019_04_004 crossref_primary_10_1016_j_nrl_2012_07_009 crossref_primary_10_1001_jamaneurol_2021_0873 crossref_primary_10_1016_j_expneurol_2020_113535 crossref_primary_10_3171_2019_5_JNS19765 crossref_primary_10_1016_j_neurol_2021_11_006 crossref_primary_10_1038_nrneurol_2013_246 crossref_primary_10_1227_neu_0000000000002601 crossref_primary_10_1016_j_jns_2013_10_044 crossref_primary_10_1016_j_jns_2014_03_017 crossref_primary_10_1161_STROKEAHA_122_040072 crossref_primary_10_1007_s12028_013_9897_z crossref_primary_10_1186_s40064_016_3495_4 crossref_primary_10_1227_NEU_0000000000000592 crossref_primary_10_1179_1743132811Y_0000000081 crossref_primary_10_3171_2020_3_JNS20375 crossref_primary_10_3389_fneur_2022_1000454 crossref_primary_10_1038_s41598_024_52527_0 crossref_primary_10_1007_s11940_012_0163_z crossref_primary_10_3390_jcm9092970 crossref_primary_10_1016_j_ncl_2021_02_006 crossref_primary_10_1177_175114371301400108 crossref_primary_10_1007_s12975_017_0594_7 crossref_primary_10_1016_j_jns_2016_06_023 crossref_primary_10_1590_acb360804 crossref_primary_10_3389_fcvm_2021_752769 crossref_primary_10_1016_j_nbd_2022_105809 crossref_primary_10_1007_s12028_021_01372_4 crossref_primary_10_1016_j_brainres_2016_05_005 crossref_primary_10_1186_s13054_016_1447_6 crossref_primary_10_1016_j_jns_2018_11_007 crossref_primary_10_1016_j_expneurol_2024_114680 crossref_primary_10_1016_j_neulet_2017_03_050 crossref_primary_10_1161_STROKEAHA_111_000773 crossref_primary_10_1097_WNQ_0000000000000159 crossref_primary_10_1016_j_jocn_2016_06_006 crossref_primary_10_1007_s10143_025_03394_4 crossref_primary_10_1089_scd_2019_0219 crossref_primary_10_1016_j_ncl_2024_07_006 crossref_primary_10_1097_MJT_0000000000000432 crossref_primary_10_1136_jnnp_2014_308778 crossref_primary_10_3171_2014_12_JNS142553 crossref_primary_10_1016_j_niox_2017_10_007 crossref_primary_10_1111_jnc_15458 crossref_primary_10_1097_WNP_0000000000000754 crossref_primary_10_1016_j_brainres_2015_05_004 crossref_primary_10_1007_s00101_012_2077_2 crossref_primary_10_1016_j_wneu_2022_11_068 crossref_primary_10_1007_s00701_012_1500_4 crossref_primary_10_1007_s12975_012_0242_1 crossref_primary_10_1097_MCC_0000000000000798 crossref_primary_10_1097_PHM_0000000000000886 crossref_primary_10_1161_HYPERTENSIONAHA_119_12105 crossref_primary_10_1007_s12975_014_0333_2 crossref_primary_10_2335_scs_44_102 crossref_primary_10_1371_journal_pone_0151853 crossref_primary_10_3171_2016_12_JNS162594 crossref_primary_10_4155_tde_11_124 crossref_primary_10_1007_s12035_014_8942_z crossref_primary_10_1016_j_anrea_2019_11_016 crossref_primary_10_4103_1673_5374_280326 crossref_primary_10_1517_13543784_2012_683113 crossref_primary_10_3171_2018_2_JNS173247 crossref_primary_10_1161_STROKEAHA_112_659888 crossref_primary_10_1097_CCE_0000000000000692 crossref_primary_10_1016_j_wneu_2013_01_006 crossref_primary_10_1002_14651858_CD008354_pub2 crossref_primary_10_1371_journal_pone_0263460 crossref_primary_10_1007_s11940_013_0278_x crossref_primary_10_1111_jebm_12660 crossref_primary_10_1111_j_1476_5381_2011_01564_x crossref_primary_10_1172_JCI130630 crossref_primary_10_1007_s12035_015_9242_y crossref_primary_10_1177_08850666211056568 crossref_primary_10_1007_s11064_016_2129_0 crossref_primary_10_1007_s12975_024_01284_3 crossref_primary_10_1038_nrneurol_2013_11 crossref_primary_10_1161_STROKEAHA_112_669788 crossref_primary_10_1177_1941874413507928 crossref_primary_10_1093_neuros_nyw141 crossref_primary_10_12688_f1000research_6635_1 crossref_primary_10_3390_cimb46090567 crossref_primary_10_1007_s12975_014_0369_3 crossref_primary_10_1007_s12028_020_01113_z crossref_primary_10_3389_fimmu_2022_823999 crossref_primary_10_1016_j_jocn_2019_08_098 crossref_primary_10_3171_2021_12_FOCUS21419 crossref_primary_10_1002_ana_25232 crossref_primary_10_1186_1471_2202_14_131 crossref_primary_10_1007_s12028_014_0084_7 crossref_primary_10_1515_tnsci_2019_0040 crossref_primary_10_1016_j_nec_2014_04_008 crossref_primary_10_1016_j_neuchi_2023_101480 crossref_primary_10_1016_j_clineuro_2022_107273 crossref_primary_10_1016_S1474_4422_11_70217_4 crossref_primary_10_1089_ars_2021_0083 crossref_primary_10_1227_NEU_0000000000000057 crossref_primary_10_1007_s12028_013_9887_1 crossref_primary_10_1007_s12975_021_00944_y crossref_primary_10_1016_j_expneurol_2011_12_039 crossref_primary_10_1161_STROKEAHA_124_047574 crossref_primary_10_1016_j_hest_2024_09_001 crossref_primary_10_3109_1354750X_2014_881418 crossref_primary_10_3389_fphar_2020_628956 crossref_primary_10_1016_j_neulet_2013_03_005 crossref_primary_10_5607_en_2014_23_1_77 crossref_primary_10_2217_fnl_13_2 crossref_primary_10_3389_fneur_2023_1296995 crossref_primary_10_1097_CNQ_0000000000000299 crossref_primary_10_1002_ana_25361 crossref_primary_10_1016_j_nec_2013_02_008 crossref_primary_10_3389_fneur_2015_00026 crossref_primary_10_3390_biomedicines11102624 crossref_primary_10_18632_aging_102788 crossref_primary_10_1038_s41598_017_09070_y crossref_primary_10_1186_1742_2094_11_1 crossref_primary_10_1016_j_wneu_2024_05_036 crossref_primary_10_1136_neurintsurg_2011_010248 crossref_primary_10_7243_2050_120X_2_18 crossref_primary_10_1161_STROKEAHA_112_674341 crossref_primary_10_1227_NEU_0b013e318285c3db crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107728 crossref_primary_10_2176_jns_nmc_2024_0204 crossref_primary_10_3390_ijms232012618 crossref_primary_10_3389_fphys_2018_00592 crossref_primary_10_4103_1673_5374_257530 crossref_primary_10_1016_j_wneu_2018_10_213 crossref_primary_10_1007_s12975_014_0355_9 crossref_primary_10_1515_tnsci_2019_0018 crossref_primary_10_1038_jcbfm_2014_108 crossref_primary_10_3389_fneur_2017_00351 crossref_primary_10_1177_0271678X17742548 crossref_primary_10_1007_s12035_018_1400_6 crossref_primary_10_1111_j_1748_1716_2011_02392_x crossref_primary_10_3390_ijms25063433 crossref_primary_10_1016_j_emc_2017_07_001 crossref_primary_10_1136_jnnp_2012_304517 crossref_primary_10_1007_s12028_013_9844_z crossref_primary_10_1161_STROKEAHA_115_006353 crossref_primary_10_1002_jnr_23475 crossref_primary_10_1016_j_jocn_2024_06_019 crossref_primary_10_1111_ene_13265 crossref_primary_10_1111_micc_12644 crossref_primary_10_1097_CCM_0000000000006332 crossref_primary_10_1007_s12028_013_9942_y crossref_primary_10_1016_j_expneurol_2022_114126 crossref_primary_10_1007_s00134_024_07387_7 crossref_primary_10_1186_s12974_019_1396_5 crossref_primary_10_3171_2015_2_JNS142752 crossref_primary_10_1016_j_brainres_2015_10_016 crossref_primary_10_3171_2014_10_JNS14290 crossref_primary_10_1016_j_wneu_2018_11_143 crossref_primary_10_2174_1570159X19666211101103646 crossref_primary_10_3390_brainsci10030153 crossref_primary_10_1007_s12975_022_01028_1 crossref_primary_10_1042_BSR20180646 crossref_primary_10_1016_j_wneu_2021_07_104 crossref_primary_10_1097_MCC_0000000000000391 crossref_primary_10_1186_s12974_017_0959_6 crossref_primary_10_1097_CCM_0000000000003373 crossref_primary_10_1097_ANA_0b013e31824a8152 crossref_primary_10_1186_s40635_014_0030_1 crossref_primary_10_3171_2015_1_JNS142757 crossref_primary_10_3390_ijms22115442 crossref_primary_10_1038_s41598_020_69028_5 crossref_primary_10_1161_STROKEAHA_112_666693 crossref_primary_10_3390_brainsci13071083 crossref_primary_10_1212_CON_0000000000001052 crossref_primary_10_1016_j_brainres_2023_148556 crossref_primary_10_1186_s12883_021_02303_8 crossref_primary_10_1016_j_clineuro_2017_04_007 crossref_primary_10_1161_STROKEAHA_111_648980 crossref_primary_10_1155_2013_425281 crossref_primary_10_1371_journal_pone_0132115 crossref_primary_10_2174_1570159X18666200914161231 crossref_primary_10_3390_jcm12031015 crossref_primary_10_1227_01_neu_0000407918_14115_e5 crossref_primary_10_1017_cjn_2022_44 crossref_primary_10_1097_ACO_0000000000000229 crossref_primary_10_1007_s00062_012_0166_x crossref_primary_10_1007_s11910_019_0990_3 crossref_primary_10_1016_j_brainres_2012_07_039 crossref_primary_10_1016_j_pneurobio_2012_02_003 crossref_primary_10_1161_STROKEAHA_113_001574 crossref_primary_10_1097_ANA_0000000000000130 crossref_primary_10_3390_ijms22126550 crossref_primary_10_1016_j_accpm_2018_10_002 crossref_primary_10_3171_2020_3_JNS193400 crossref_primary_10_1073_pnas_1121359109 crossref_primary_10_1016_j_biopha_2018_08_012 crossref_primary_10_1016_j_wneu_2019_04_222 crossref_primary_10_1111_jnc_15511 crossref_primary_10_1016_j_jocn_2017_05_031 crossref_primary_10_1016_j_wneu_2022_01_033 crossref_primary_10_1227_NEU_0b013e31828048ce crossref_primary_10_1016_j_hest_2020_04_003 crossref_primary_10_1007_s11910_021_01136_9 crossref_primary_10_1080_00207454_2019_1709845 crossref_primary_10_1111_jth_12511 crossref_primary_10_1186_s13063_019_3517_y crossref_primary_10_1016_j_jns_2018_02_039 crossref_primary_10_3389_fneur_2023_1280047 |
| Cites_doi | 10.1161/STROKEAHA.108.519942 10.1161/STROKEAHA.108.533315 10.1016/S1474-4422(10)70087-9 10.1002/jnr.21823 10.1161/01.STR.30.11.2347 10.1161/01.STR.0000048217.44714.02 10.1093/brain/awl297 10.1016/j.drudis.2007.11.010 10.1007/s12028-010-9433-3 10.1161/STROKEAHA.109.571125 10.1038/jcbfm.2008.74 10.1161/STROKEAHA.108.191395 10.1007/s12028-008-9147-y 10.1212/WNL.55.5.658 10.3171/jns.1990.73.1.0018 10.1161/STROKEAHA.109.560243 10.1016/S0140-6736(74)91639-0 10.1161/01.STR.31.11.2742 10.1038/ncpneuro0490 10.3171/jns.2005.103.1.0009 10.1038/jcbfm.2011.7 10.1161/STROKEAHA.109.556332 10.1212/01.WNL.0000035748.91128.C2 10.1161/01.STR.16.4.562 |
| ContentType | Journal Article |
| Copyright | 2011 Elsevier Ltd Elsevier Ltd Copyright © 2011 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jul 2011 |
| Copyright_xml | – notice: 2011 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jul 2011 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8C2 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1016/S1474-4422(11)70108-9 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Pharma and Biotech Premium PRO ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE - Academic ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-4465 |
| EndPage | 625 |
| ExternalDocumentID | 2381769791 21640651 10_1016_S1474_4422_11_70108_9 S1474442211701089 1_s2_0_S1474442211701089 |
| Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Actelion Pharmaceuticals. |
| GroupedDBID | --- --K --M -RU .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 8AO 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABIVO ABJNI ABMAC ABMZM ABOCM ABTEW ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGWIK AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP AXJTR AZQEC BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HF~ HMCUK HVGLF HZ~ IHE J1W JCF KOM M1P M2M M41 MO0 N9A NAPCQ O-L O9- OP~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PUEGO ROL RPZ SDG SEL SES SPCBC SSH SSN SSZ T5K TLN UHS UKHRP UV1 WOW XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AADPK ABLVK ABYKQ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c532t-b79b6185ee268ae8e429b073e2b2e28123316766623a007a9f413cf00e6f454d3 |
| IEDL.DBID | 7X7 |
| ISSN | 1474-4422 1474-4465 |
| IngestDate | Fri Jul 11 03:22:14 EDT 2025 Thu Jul 10 19:26:38 EDT 2025 Fri Jul 25 04:17:28 EDT 2025 Thu Apr 03 06:57:01 EDT 2025 Tue Jul 01 02:24:34 EDT 2025 Thu Apr 24 23:09:56 EDT 2025 Fri Feb 23 02:28:58 EST 2024 Sun Feb 23 10:18:50 EST 2025 Tue Aug 26 16:33:24 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2011 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c532t-b79b6185ee268ae8e429b073e2b2e28123316766623a007a9f413cf00e6f454d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 ObjectType-Feature-1 |
| PMID | 21640651 |
| PQID | 873311782 |
| PQPubID | 26255 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_883045415 proquest_miscellaneous_873122217 proquest_journals_873311782 pubmed_primary_21640651 crossref_primary_10_1016_S1474_4422_11_70108_9 crossref_citationtrail_10_1016_S1474_4422_11_70108_9 elsevier_sciencedirect_doi_10_1016_S1474_4422_11_70108_9 elsevier_clinicalkeyesjournals_1_s2_0_S1474442211701089 elsevier_clinicalkey_doi_10_1016_S1474_4422_11_70108_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-07-01 |
| PublicationDateYYYYMMDD | 2011-07-01 |
| PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Lancet neurology |
| PublicationTitleAlternate | Lancet Neurol |
| PublicationYear | 2011 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Bederson, Awad, Wiebers (bib14) 2000; 31 Hackett, Anderson (bib1) 2000; 55 Egge, Waterloo, Sjøholm, Solberg, Ingebrigtsen, Romner (bib7) 2001; 49 Kramer, Fletcher (bib10) 2009; 40 Schlegel, Kolb, Luciano (bib16) 2003; 34 Jang, Ilodigwe, Macdonald (bib24) 2009; 10 Macdonald, Pluta, Zhang (bib20) 2007; 3 Mayer, Kreiter, Copeland (bib2) 2002; 59 Macdonald, Higashida, Keller (bib13) 2010; 13 Dreier, Woitzik, Fabricius (bib21) 2006; 129 Rabinstein, Lanzino, Wijdicks (bib8) 2010; 9 Vergouwen, Vermeulen, Coert, Stroes, Roos (bib22) 2008; 28 Lyden, Lu, Jackson (bib17) 1999; 30 Vergouwen, de Haan, Vermeulen, Roos (bib25) 2010; 41 Kassell, Saski, Colohan, Nazar (bib3) 1985; 16 Kassell, Turner, Haley, Jane, Adams, Kongable (bib4) 1990; 73 Macdonald, Kassell, Mayer (bib12) 2008; 39 Bederson, Connolly, Batjer (bib18) 2009; 40 Crowley, Medel, Kassell, Dumont (bib5) 2008; 13 Vajkoczy, Meyer, Weidauer (bib11) 2005; 103 Kolias, Sen, Belli (bib9) 2009; 87 Cahill, Zhang (bib23) 2009; 40 Wong, Poon, Chan (bib26) 2010; 41 Etminan, Vergouwen, Ilodigwe, Macdonald (bib19) 2011 Dorhout Mees, Rinkel, Feigin (bib6) 2007; 3 Teasdale, Jennet (bib15) 1974; 2 Etminan (10.1016/S1474-4422(11)70108-9_bib19) 2011 Cahill (10.1016/S1474-4422(11)70108-9_bib23) 2009; 40 Macdonald (10.1016/S1474-4422(11)70108-9_bib13) 2010; 13 Macdonald (10.1016/S1474-4422(11)70108-9_bib12) 2008; 39 Schlegel (10.1016/S1474-4422(11)70108-9_bib16) 2003; 34 Bederson (10.1016/S1474-4422(11)70108-9_bib18) 2009; 40 Mayer (10.1016/S1474-4422(11)70108-9_bib2) 2002; 59 Vergouwen (10.1016/S1474-4422(11)70108-9_bib25) 2010; 41 Rabinstein (10.1016/S1474-4422(11)70108-9_bib8) 2010; 9 Vergouwen (10.1016/S1474-4422(11)70108-9_bib22) 2008; 28 Vajkoczy (10.1016/S1474-4422(11)70108-9_bib11) 2005; 103 Kramer (10.1016/S1474-4422(11)70108-9_bib10) 2009; 40 Kassell (10.1016/S1474-4422(11)70108-9_bib3) 1985; 16 Kassell (10.1016/S1474-4422(11)70108-9_bib4) 1990; 73 Kolias (10.1016/S1474-4422(11)70108-9_bib9) 2009; 87 Macdonald (10.1016/S1474-4422(11)70108-9_bib20) 2007; 3 Egge (10.1016/S1474-4422(11)70108-9_bib7) 2001; 49 Hackett (10.1016/S1474-4422(11)70108-9_bib1) 2000; 55 Wong (10.1016/S1474-4422(11)70108-9_bib26) 2010; 41 Dorhout Mees (10.1016/S1474-4422(11)70108-9_bib6) 2007; 3 Bederson (10.1016/S1474-4422(11)70108-9_bib14) 2000; 31 Lyden (10.1016/S1474-4422(11)70108-9_bib17) 1999; 30 Crowley (10.1016/S1474-4422(11)70108-9_bib5) 2008; 13 Dreier (10.1016/S1474-4422(11)70108-9_bib21) 2006; 129 Jang (10.1016/S1474-4422(11)70108-9_bib24) 2009; 10 Teasdale (10.1016/S1474-4422(11)70108-9_bib15) 1974; 2 21640652 - Lancet Neurol. 2011 Jul;10(7):593-5 21939894 - Lancet Neurol. 2011 Oct;10(10):871; author reply 871-2 27423597 - J Neurol Sci. 2016 Aug 15;367 :244 |
| References_xml | – volume: 40 start-page: 3403 year: 2009 end-page: 3406 ident: bib10 article-title: Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis publication-title: Stroke – volume: 40 start-page: 994 year: 2009 end-page: 1025 ident: bib18 article-title: Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association publication-title: Stroke – volume: 9 start-page: 504 year: 2010 end-page: 519 ident: bib8 article-title: Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage publication-title: Lancet Neurol – volume: 55 start-page: 658 year: 2000 end-page: 662 ident: bib1 article-title: Health outcomes 1 year after subarachnoid hemorrhage. An international population-based study publication-title: Neurology – volume: 87 start-page: 1 year: 2009 end-page: 11 ident: bib9 article-title: Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches publication-title: J Neurosci Res – volume: 103 start-page: 9 year: 2005 end-page: 17 ident: bib11 article-title: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study publication-title: J Neurosurg – volume: 16 start-page: 562 year: 1985 end-page: 572 ident: bib3 article-title: Cerebral vasospasm following aneurysmal subarachnoid hemorrhage publication-title: Stroke – volume: 40 start-page: S86 year: 2009 end-page: S87 ident: bib23 article-title: Subarachnoid hemorrhage: is it time for a new direction? publication-title: Stroke – volume: 13 start-page: 254 year: 2008 end-page: 260 ident: bib5 article-title: New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage publication-title: Drug Discovery – volume: 39 start-page: 3015 year: 2008 end-page: 3021 ident: bib12 article-title: Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial publication-title: Stroke – volume: 73 start-page: 18 year: 1990 end-page: 36 ident: bib4 article-title: The International Cooperative Study on the Timing of Aneurysm Surgery: Part 1–overall management results publication-title: J Neurosurg – volume: 129 start-page: 3224 year: 2006 end-page: 3237 ident: bib21 article-title: Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations publication-title: Brain – volume: 10 start-page: 141 year: 2009 end-page: 147 ident: bib24 article-title: Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage publication-title: Neurocrit Care – volume: 31 start-page: 2742 year: 2000 end-page: 2750 ident: bib14 article-title: Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association publication-title: Stroke – volume: 13 start-page: 416 year: 2010 end-page: 424 ident: bib13 article-title: Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials publication-title: Neurocrit Care – volume: 30 start-page: 2347 year: 1999 end-page: 2354 ident: bib17 article-title: Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators publication-title: Stroke – volume: 41 start-page: 921 year: 2010 end-page: 926 ident: bib26 article-title: Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial publication-title: Stroke – year: 2011 ident: bib19 article-title: Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis publication-title: J Cereb Blood Flow Metab – volume: 41 start-page: e47 year: 2010 end-page: e52 ident: bib25 article-title: Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update publication-title: Stroke – volume: 28 start-page: 1761 year: 2008 end-page: 1770 ident: bib22 article-title: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia publication-title: J Cereb Blood Flow Metab – volume: 34 start-page: 134 year: 2003 end-page: 137 ident: bib16 article-title: Utility of the NIH Stroke Scale as a predictor of hospital disposition publication-title: Stroke – volume: 49 start-page: 593 year: 2001 end-page: 606 ident: bib7 article-title: Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study publication-title: Neurosurgery – volume: 3 year: 2007 ident: bib6 article-title: Calcium antagonists for aneurysmal subarachnoid haemorrhage publication-title: Cochrane Database Syst Rev – volume: 59 start-page: 1750 year: 2002 end-page: 1758 ident: bib2 article-title: Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage publication-title: Neurology – volume: 3 start-page: 256 year: 2007 end-page: 263 ident: bib20 article-title: Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution publication-title: Nat Clin Pract Neurol – volume: 2 start-page: 81 year: 1974 end-page: 84 ident: bib15 article-title: Assessment of coma and impaired consciousness. A practical scale publication-title: Lancet – volume: 39 start-page: 3015 year: 2008 ident: 10.1016/S1474-4422(11)70108-9_bib12 article-title: Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial publication-title: Stroke doi: 10.1161/STROKEAHA.108.519942 – volume: 40 start-page: S86 year: 2009 ident: 10.1016/S1474-4422(11)70108-9_bib23 article-title: Subarachnoid hemorrhage: is it time for a new direction? publication-title: Stroke doi: 10.1161/STROKEAHA.108.533315 – volume: 9 start-page: 504 year: 2010 ident: 10.1016/S1474-4422(11)70108-9_bib8 article-title: Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70087-9 – volume: 87 start-page: 1 year: 2009 ident: 10.1016/S1474-4422(11)70108-9_bib9 article-title: Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches publication-title: J Neurosci Res doi: 10.1002/jnr.21823 – volume: 30 start-page: 2347 year: 1999 ident: 10.1016/S1474-4422(11)70108-9_bib17 article-title: Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators publication-title: Stroke doi: 10.1161/01.STR.30.11.2347 – volume: 34 start-page: 134 year: 2003 ident: 10.1016/S1474-4422(11)70108-9_bib16 article-title: Utility of the NIH Stroke Scale as a predictor of hospital disposition publication-title: Stroke doi: 10.1161/01.STR.0000048217.44714.02 – volume: 129 start-page: 3224 year: 2006 ident: 10.1016/S1474-4422(11)70108-9_bib21 article-title: Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations publication-title: Brain doi: 10.1093/brain/awl297 – volume: 13 start-page: 254 year: 2008 ident: 10.1016/S1474-4422(11)70108-9_bib5 article-title: New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage publication-title: Drug Discovery doi: 10.1016/j.drudis.2007.11.010 – volume: 13 start-page: 416 year: 2010 ident: 10.1016/S1474-4422(11)70108-9_bib13 article-title: Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials publication-title: Neurocrit Care doi: 10.1007/s12028-010-9433-3 – volume: 41 start-page: 921 year: 2010 ident: 10.1016/S1474-4422(11)70108-9_bib26 article-title: Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial publication-title: Stroke doi: 10.1161/STROKEAHA.109.571125 – volume: 28 start-page: 1761 year: 2008 ident: 10.1016/S1474-4422(11)70108-9_bib22 article-title: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2008.74 – volume: 40 start-page: 994 year: 2009 ident: 10.1016/S1474-4422(11)70108-9_bib18 article-title: Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association publication-title: Stroke doi: 10.1161/STROKEAHA.108.191395 – volume: 10 start-page: 141 year: 2009 ident: 10.1016/S1474-4422(11)70108-9_bib24 article-title: Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage publication-title: Neurocrit Care doi: 10.1007/s12028-008-9147-y – volume: 55 start-page: 658 year: 2000 ident: 10.1016/S1474-4422(11)70108-9_bib1 article-title: Health outcomes 1 year after subarachnoid hemorrhage. An international population-based study publication-title: Neurology doi: 10.1212/WNL.55.5.658 – volume: 73 start-page: 18 year: 1990 ident: 10.1016/S1474-4422(11)70108-9_bib4 article-title: The International Cooperative Study on the Timing of Aneurysm Surgery: Part 1–overall management results publication-title: J Neurosurg doi: 10.3171/jns.1990.73.1.0018 – volume: 40 start-page: 3403 year: 2009 ident: 10.1016/S1474-4422(11)70108-9_bib10 article-title: Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis publication-title: Stroke doi: 10.1161/STROKEAHA.109.560243 – volume: 2 start-page: 81 year: 1974 ident: 10.1016/S1474-4422(11)70108-9_bib15 article-title: Assessment of coma and impaired consciousness. A practical scale publication-title: Lancet doi: 10.1016/S0140-6736(74)91639-0 – volume: 31 start-page: 2742 year: 2000 ident: 10.1016/S1474-4422(11)70108-9_bib14 article-title: Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association publication-title: Stroke doi: 10.1161/01.STR.31.11.2742 – volume: 3 start-page: 256 year: 2007 ident: 10.1016/S1474-4422(11)70108-9_bib20 article-title: Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution publication-title: Nat Clin Pract Neurol doi: 10.1038/ncpneuro0490 – volume: 49 start-page: 593 year: 2001 ident: 10.1016/S1474-4422(11)70108-9_bib7 article-title: Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study publication-title: Neurosurgery – volume: 103 start-page: 9 year: 2005 ident: 10.1016/S1474-4422(11)70108-9_bib11 article-title: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study publication-title: J Neurosurg doi: 10.3171/jns.2005.103.1.0009 – year: 2011 ident: 10.1016/S1474-4422(11)70108-9_bib19 article-title: Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2011.7 – volume: 41 start-page: e47 year: 2010 ident: 10.1016/S1474-4422(11)70108-9_bib25 article-title: Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update publication-title: Stroke doi: 10.1161/STROKEAHA.109.556332 – volume: 59 start-page: 1750 year: 2002 ident: 10.1016/S1474-4422(11)70108-9_bib2 article-title: Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage publication-title: Neurology doi: 10.1212/01.WNL.0000035748.91128.C2 – volume: 16 start-page: 562 year: 1985 ident: 10.1016/S1474-4422(11)70108-9_bib3 article-title: Cerebral vasospasm following aneurysmal subarachnoid hemorrhage publication-title: Stroke doi: 10.1161/01.STR.16.4.562 – volume: 3 year: 2007 ident: 10.1016/S1474-4422(11)70108-9_bib6 article-title: Calcium antagonists for aneurysmal subarachnoid haemorrhage publication-title: Cochrane Database Syst Rev – reference: 21640652 - Lancet Neurol. 2011 Jul;10(7):593-5 – reference: 21939894 - Lancet Neurol. 2011 Oct;10(10):871; author reply 871-2 – reference: 27423597 - J Neurol Sci. 2016 Aug 15;367 :244 |
| SSID | ssj0021481 |
| Score | 2.5486202 |
| Snippet | Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage... Summary Background Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 618 |
| SubjectTerms | Anemia Aneurysm Cardiovascular system Cerebral infarction Clinical trials Coiling Dioxanes - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Endothelin A Receptor Antagonists Endothelin receptors Female Glasgow Outcome Scale Humans Hypotension Lung Male Morbidity Mortality Neurology Pharmaceuticals Pyridines - therapeutic use Pyrimidines - therapeutic use Risk assessment subarachnoid hemorrhage Subarachnoid Hemorrhage - complications Subarachnoid Hemorrhage - drug therapy Subarachnoid Hemorrhage - mortality Subarachnoid Hemorrhage - surgery Sulfonamides - therapeutic use Surgical Instruments Tetrazoles - therapeutic use Treatment Outcome Vasoconstriction Vasospasm, Intracranial - drug therapy Vasospasm, Intracranial - etiology Vasospasm, Intracranial - mortality Vasospasm, Intracranial - prevention & control |
| Title | Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1474442211701089 https://www.clinicalkey.es/playcontent/1-s2.0-S1474442211701089 https://dx.doi.org/10.1016/S1474-4422(11)70108-9 https://www.ncbi.nlm.nih.gov/pubmed/21640651 https://www.proquest.com/docview/873311782 https://www.proquest.com/docview/873122217 https://www.proquest.com/docview/883045415 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF5BKyEuiHdDodoDh1aKqb1-hguCqFVBaooIkXpbeb3jBinYIU4u_Ef-E9_YG_dCW27JekdreWZnvtmZnRHirQ1h1CgovSwm40UF_wpHsWcKynO_NDYu2VE8nyRns-jLZXzpcnMal1a51YmtorZ1wWfkxxk3Fwxgzz4sf3ncNIqDq66Dxn2xy5XLWKjTy2t_C0i_9beiNPKiSKnrCzzH037wMAiOUjgl2PY3maaboGdrgk4fi0cOO8qPHbOfiHtUPRUPzl10_Jn4M17kv-v2NlE1lHklqbJ8wQpIUkKx0RL-NYY5DsX1cocS466uaiP5QBYPCd-4-YlVmg3HIfjc_YeV85wTcldzKB_Jt85WVzVMHuasWsUpi0Vb5-HqvcwljJ-tIT1kh9LWG7Mgz-AN8K_N_zK159LjF2Tlcg4rKkPZNg-Rh-OLyXT8-WI29dTRczE7Pfk-PvNcuwaviEO19kw6MgnMP5FKspwygqkz0CCkjCIFIBHyrXu4SyrMgUzyUQkDWpS-T0kZxZENX4idqq5oT8gy9EsKshFFKfz3BMRpCuZbygpfUZwMRLTllC5cLXNuqbHQfdIaM1gzg-Hj6JbBejQQ73qyZVfM4y6CZCsGentTFbpVw9zcRZj-i5AapyEaHehGab-jZmLuAARSUGY9pQNBHbj5n0X3t5Kq-3X6fTMQsn8KIeC4EISq3rRTAsDEIL1lSsYRdYC9gXjZbYH-Ayo43MCxwatbV98XD7vTeE50fi121qsNvQGcW5uDdtMeiN1PJ5Ov3_4CLUdFZw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgEXxJtQHnsAqZViaq-fQUIIBaqENukhjZTb1o9xgxTsECdC8J_4KfwnvvGrF9py6S1Z72StzOx8MzszO0K8TmyAGlmpEbgUGU7Mn-yea0QxhaGZRombsqM4GnuDqfNl5s62xO-mFobTKhudWCrqJI_5jHw_4OaCFvDsw_K7wU2jOLjadNCopOKQfv6Ax1a8H34Ce98odfD5pD8w6qYCRuzaam1Efi_yAFJEygtCCggKOYKck4oUKcCdzbXhMOqVHQI_w14KNR-npkle6rhOYuN3b4ibwF2TfT1_du7fwbMo_TvHdwzHUeq8YGh_0g7uWtaeDycIauYiKLzI1C0h7-CeuFvbqvJjJVz3xRZlD8StUR2Nfyj-9Bfhr7ysXsq6MswkZQkXdMFylVCktIQ_j2GOe_H9vF2J8foe10LyATAeEnhafMMqxYbjHnzO_zWR85ATgFdzKDvJVW6rsxwQizmrUlHLeFHeK3H2ToYSYJvkkFZKujLJN9GCjAhvgG9lvlmUG3U6_oISuZwDtaUty2Ylcrd_PJ70h8fTiaH2HonptXDysdjO8oyeCpnaZkpW0CPHNx0QBJbvQ9gSCmJTket1hNNwSsf13encwmOh2yQ5ZrBmBsOn0iWDda8j3rZky-rykKsIvEYMdFMZC12uAW9XEfr_IqSi1kiFtnShtFlRMzF3HAIpKIOWsja6KmPqfxbdaSRVt-u0-7QjZPsUQsBxKAhVvimnWDBLLf-SKQFH8GFcdsSTagu0f6CCgw-72Xp26eqvxO3ByehIHw3HhzviThUJ4CTr52J7vdrQC5iS6-hluYGlOL1ujfEXYth-hA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxNBDB6VVKq4IN6E8pgDSK2UJbuzzyAhBGmjhtK0IkTqbboPb4MUsiGbCME_40fwn_i8Ly605dJbMjvOrGLPZ3tsj4V4kdhQamSlRuBSZDgxf7J7rhHFFIZmGiVuyo7i0cg7mDgfTt3TDfGrroXhtMoaEwugTrKYz8i7ATcXtKDPummVFXGyN3i7-GZwAykOtNbdNEoJOaQf3-G95W-Ge2D1S6UG-5_7B0bVYMCIXVutjMjvRR4UFpHygpACAjhHkHlSkSIF1WdznTgMfGWH0KVhLwXkx6lpkpc6rpPY-N0bYtNnp6glNt_vj04-Nd4e_IzC23N8x3Acpf6WD3XHzeCOZe36cIkAOhcpxosM30IBDm6LW5XlKt-VonZHbND8rtg6qmLz98Tv_iz8mRW1TPOODOeS5gmXd8GOlYBVWsC7xzBHwfi23o7EeHWray75OBgPCRzOv2KVfM1RED71_5LIacjpwMspoE9yzdvyPIPCxZxlAdsynhW3TJy_lqGE6k0yyC4lHZlk62hGRoQ3wLci-yzKjCo5f0aJXEyhw6Uti9Ylcqd_PBr3h8eTsaF274vJtfDygWjNszk9EjK1zZSsoEeObzogCCzfh-glFMSmItdrC6fmlI6rm9S5ocdMNylzzGDNDIaHpQsG615bvGrIFuVVIlcReLUY6LpOFsiuoeyuIvT_RUh5hU-5tnSutFlSMzH3HwIpKIOGsjLBStPqfxbdriVVN-s0u7YtZPMUQsBRKQhVti6mWDBSLf-SKQHH82FqtsXDcgs0f6CCuw8r2np86erPxRbQQn8cjg63xc0yLMAZ109Ea7Vc01PYlavoWbWDpTi7btD4A1UZhB8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clazosentan%2C+an+endothelin+receptor+antagonist%2C+in+patients+with+aneurysmal+subarachnoid+haemorrhage+undergoing+surgical+clipping%3A+a+randomised%2C+double-blind%2C+placebo-controlled+phase+3+trial+%28CONSCIOUS-2%29&rft.jtitle=Lancet+neurology&rft.au=Macdonald%2C+R+Loch%2C+Dr&rft.au=Higashida%2C+Randall+T%2C+MD&rft.au=Keller%2C+Emanuela%2C+MD&rft.au=Mayer%2C+Stephan+A%2C+MD&rft.date=2011-07-01&rft.issn=1474-4422&rft.volume=10&rft.issue=7&rft.spage=618&rft.epage=625&rft_id=info:doi/10.1016%2FS1474-4422%2811%2970108-9&rft.externalDBID=ECK1-s2.0-S1474442211701089&rft.externalDocID=1_s2_0_S1474442211701089 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14744422%2FS1474442211X70060%2Fcov150h.gif |